---
title: "Left ventricular hypertrophy and brain atrophy in type 2 diabetes: findings from the D2 cohort"
id: "medrxiv-0-left-ventricular-hypertrophy-brain-atrophy-and-cognitive-decline-in-type-2"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-left-ventricular-hypertrophy-brain-atrophy-and-cognitive-decline-in-type-2"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Left ventricular hypertrophy and brain atrophy in type 2 diabetes: findings from the D2 cohort
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-left-ventricular-hypertrophy-brain-atrophy-and-cognitive-decline-in-type-2
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This multicentre observational Diabetes & Dementia (D2) cohort study assessed brain volume and cognitive trajectories over 2 years in people with **type 2 diabetes mellitus (T2DM)**. Participants underwent baseline and 2-year brain MRI, transthoracic echocardiography (TTE) and cognitive testing. - Recruitment ran from 20 May 2016 to 20 March 2020. Of 2,378 screened, 702 were eligible, 196 consented, 150 completed baseline assessments and 123 completed full 2-year follow-up with complete MRI, TTE and cognitive data (17.4% attrition). - Baseline left ventricular hypertrophy (**LVH**) was associated with female sex, older age, lower education, lower mood, hypertension, obesity, beta-blocker use, and smaller total brain volume (**TBV**). - Participants with baseline cognitive impairment showed greater brain atrophy over 2 years. Lower education, hypertension, and lower baseline cognitive scores predicted cognitive decline. - Using inverse probability of treatment weighting for causal inference and excluding participants with non-positivity on age and baseline TBV, analysis included 62 without LVH and 31 with LVH. The presence of LVH was associated with a **lower TBV change** (standardized mean difference 6.3 cm3, 95% CI 0.1–12.5, P = .048). - LVH had no detectable effect on cognitive decline over 2 years in this cohort. - The authors conclude that LVH-treated patients (for example with beta-blockers) may derive both cardioprotective and neuroprotective benefits, and they note guideline-directed LVH therapies could be relevant. Trial registration and ethics approvals were reported; no competing interests declared.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Left ventricular hypertrophy, brain atrophy and cognitive decline in type 2 diabetes mellitus: Diabetes & Dementia (D2) cohort study [ View ORCID Profile](http://orcid.org/0000-0001-9466-2862)Amy Brodtmann, [ View ORCID Profile](http://orcid.org/0000-0002-0626-1899)Sheila Patel, Carolina Restrepo, [ View ORCID Profile](http://orcid.org/0000-0002-0096-434X)Mohamed Salah Khlif, Emilio Werden, Rachel Ellis, Shahad Alsawaf, [ View ORCID Profile](http://orcid.org/0000-0003-2372-395X)Elif I. Ekinci, [ View ORCID Profile](http://orcid.org/0000-0002-8129-3137)Piyush M Srivastava, [ View ORCID Profile](http://orcid.org/0000-0001-8591-1986)Jay Ramchand, Richard J MacIsaac, [ View ORCID Profile](http://orcid.org/0000-0002-9807-6606)Leonid Churilov, [ View ORCID Profile](http://orcid.org/0000-0003-1863-7539)Louise M. Burrell doi: https://doi.org/10.64898/2026.08.31.26361868 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Amy Brodtmann 1 Monash University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amy%2BBrodtmann%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Brodtmann%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmy%2BBrodtmann%2B) * [ORCID record for Amy Brodtmann](http://orcid.org/0000-0001-9466-2862 "Open in new tab") * For correspondence: amy.brodtmann@monash.edu Sheila Patel 2 University of Melbourne; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sheila%2BPatel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Patel%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASheila%2BPatel%2B) * [ORCID record for Sheila Patel](http://orcid.org/0000-0002-0626-1899 "Open in new tab") Carolina Restrepo 3 Cabrini Specialist Centre & Cabrini Women?s Mental Health Centre; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Carolina%2BRestrepo%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Restrepo%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACarolina%2BRestrepo%2B) Mohamed Salah Khlif 4 Monash University School of Translational Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mohamed%2BSalah%2BKhlif%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Khlif%20MS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMohamed%2BSalah%2BKhlif%2B) * [ORCID record for Mohamed Salah Khlif](http://orcid.org/0000-0002-0096-434X "Open in new tab") Emilio Werden 5 The Florey Institute of Neuroscience and Mental Health; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Emilio%2BWerden%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Werden%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEmilio%2BWerden%2B) Rachel Ellis 4 Monash University School of Translational Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rachel%2BEllis%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ellis%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARachel%2BEllis%2B) Shahad Alsawaf 4 Monash University School of Translational Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shahad%2BAlsawaf%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Alsawaf%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AShahad%2BAlsawaf%2B) Elif I. Ekinci 6 Austin Health; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elif%2BI.%2BEkinci%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ekinci%20EI&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AElif%2BI.%2BEkinci%2B) * [ORCID record for Elif I. Ekinci](http://orcid.org/0000-0003-2372-395X "Open in new tab") Piyush M Srivastava 7 The University of Melbourne Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Piyush%2BM%2BSrivastava%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Srivastava%20PM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APiyush%2BM%2BSrivastava%2B) * [ORCID record for Piyush M Srivastava](http://orcid.org/0000-0002-8129-3137 "Open in new tab") Jay Ramchand 8 The Cleveland Clinic Foundation; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jay%2BRamchand%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ramchand%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJay%2BRamchand%2B) * [ORCID record for Jay Ramchand](http://orcid.org/0000-0001-8591-1986 "Open in new tab") Richard J MacIsaac 9 St Vincent's Hospital Melbourne; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Richard%2BJ%2BMacIsaac%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=MacIsaac%20RJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARichard%2BJ%2BMacIsaac%2B) Leonid Churilov 10 The University of Melbourne * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Leonid%2BChurilov%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Churilov%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALeonid%2BChurilov%2B) * [ORCID record for Leonid Churilov](http://orcid.org/0000-0002-9807-6606 "Open in new tab") Louise M. Burrell 7 The University of Melbourne Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Louise%2BM.%2BBurrell%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Burrell%20LM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALouise%2BM.%2BBurrell%2B) * [ORCID record for Louise M. Burrell](http://orcid.org/0000-0003-1863-7539 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1290679/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1290679/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1290679/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1290679/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1290679/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract BACKGROUND People with type 2 diabetes mellitus (T2DM) are at higher risk of cerebral small vessel disease and left ventricular hypertrophy (LVH), potentially contributing to cognitive decline and dementia. We aimed to describe brain volume and cognitive trajectories over 2 years in a cohort of people with T2DM and to determine whether LVH causes increased brain atrophy and cognitive decline. METHODS Diabetes and Dementia (D2) study is a multicentre observational cohort study in Melbourne, Australia. Participants aged >50 years were recruited via 2 hospital outpatient clinics, 3 private clinics, and study advertisements. Participants with pre-existing cognitive impairment, life-limiting medical illness, and severe chronic renal impairment were excluded. Participants attended study visits for brain MRI, transthoracic echocardiography (TTE), and cognitive testing at baseline and 2 years. The exposure was LVH determined on baseline TTE. Pre-specified outcomes were total brain volume (TBV) change and cognitive decline (z-score change?-1 in any cognitive domain) over 2 years. Regression analyses examined associations between baseline variables and outcomes. A causal inference approach was utilized using inverse probability of treatment weighting to standardize for confounding covariates, excluding participants for non-positivity on age and baseline TBV. RESULTS Participants were recruited 20May2016 to 20March2020: 2378 screened, 702 eligible, 196 consented, 150 baseline and 123 2-year assessments with complete MRI, TTE, and cognitive data (17.4% attrition). At baseline, LVH was associated with female sex, older age, lower educational attainment, lower mood, hypertension, obesity, beta-blocker use, and smaller TBV. Participants with baseline cognitive impairment exhibited greater brain atrophy. Lower educational attainment, hypertension, and lower baseline cognitive scores were associated with cognitive decline. Causal inference analysis included 62 participants with no LVH (20(32%) women; mean [SD]=66.9[5.9] years), and 31 with LVH (17(55%) women, 67.4[5.4] years). LVH caused lower TBV change: standardized mean difference (95% CI) 6.3 (0.1, 12.5) cm3, P=.048. LVH had no effect on cognitive decline. CONCLUSIONS Brain atrophy and cognitive decline were associated with baseline cognitive impairment. LVH caused less brain atrophy and cognitive decline in people with T2DM. We conclude that guideline-directed LVH therapies such as beta-blockers have both cardioprotective (remodelling) and neuroprotective effects. TRIAL REGISTRATION ACTRN12616000546459 UTN: U1111-1181-6659 ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial Australian and New Zealand Clinical Trials website ACTRN12616000546459 ### Clinical Protocols ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics approval was received from the Human Research Ethics Committee of Austin Health (24 March 2016, HREC/15/Austin/490). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Data collected for the study, including individual participant data and a data dictionary defining each field in the set, will be made available upon reasonable request. Proposals should be sent to the corresponding author for approval from the Steering Committee. Deidentified participant data, data dictionary, and imaging analysis pipelines could be shared from Jan 1, 2027. The study protocols, statistical analysis plan, and informed consent form are available from the Australian and New Zealand Clinical Trials website ACTRN12616000546459. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1 "Benchmarking ten frontier large language models on 1,477 board style multiple choice questions in hematology") Posted September 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/02/2026.08.31.26361868.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.31.26361868v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/02/2026.08.31.26361868.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Left ventricular hypertrophy, brain atrophy and cognitive decline in type 2 diabetes mellitus: Diabetes & Dementia (D2) cohort study Amy Brodtmann, Sheila Patel, Carolina Restrepo, Mohamed Salah Khlif, Emilio Werden, Rachel Ellis, Shahad Alsawaf, Elif I. Ekinci, Piyush M Srivastava, Jay Ramchand, Richard J MacIsaac, Leonid Churilov, Louise M. Burrell medRxiv 2026.08.31.26361868; doi: https://doi.org/10.64898/2026.08.31.26361868 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.31.26361868v1%26text%3DLeft%2520ventricular%2520hypertrophy%252C%2520brain%2520atrophy%2520and%2520cognitive%2520decline%2520in%2520type%25202%2520diabetes%2520mellitus%253A%2520Diabetes%2520%2526%2520Dementia%2520%2528D2%2529%2520cohort%2520study "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.31.26361868v1%26t%3DLeft%2520ventricular%2520hypertrophy%252C%2520brain%2520atrophy%2520and%2520cognitive%2520decline%2520in%2520type%25202%2520diabetes%2520mellitus%253A%2520Diabetes%2520%2526%2520Dementia%2520%2528D2%2529%2520cohort%2520study "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.31.26361868v1%26title%3DLeft%2520ventricular%2520hypertrophy%252C%2520brain%2520atrophy%2520and%2520cognitive%2520decline%2520in%2520type%25202%2520diabetes%2520mellitus%253A%2520Diabetes%2520%2526%2520Dementia%2520%2528D2%2529%2520cohort%2520study%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.31.26361868v1%26title%3DLeft%2520ventricular%2520hypertrophy%252C%2520brain%2520atrophy%2520and%2520cognitive%2520decline%2520in%2520type%25202%2520diabetes%2520mellitus%253A%2520Diabetes%2520%2526%2520Dementia%2520%2528D2%2529%2520cohort%2520study "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.31.26361868) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.31.26361868v1&count=horizontal&via=&text=Left%20ventricular%20hypertrophy%2C%20brain%20atrophy%20and%20cognitive%20decline%20in%20type%202%20diabetes%20mellitus%3A%20Diabetes%20%26%20Dementia%20%28D
## Related Clinical Research

- [ENDO 2026: Progress and Resilience in Endocrinology and Obesity Care](https://medichelpline.com/clinical-feed/endocrine-news-0-endo-2026-progress-and-resilience.md)
- [Testosterone Therapy in Men Often Prescribed Inconsistently with Guidelines, ENDO 2026 Study Shows](https://medichelpline.com/clinical-feed/endocrine-news-0-video-testosterone-therapy-in-men-may-be-overprescribed-inconsistent-with.md)
- [Single-cell scTWAS identifies immune cell–specific genes linked to gestational diabetes](https://medichelpline.com/clinical-feed/plos-one-0-leveraging-expression-quantitative-trait-loci-information-in-single-cell.md)
- [Semaglutide withdrawal strategies and recovery of cardiometabolic and energy-balance physiology: R](https://medichelpline.com/clinical-feed/plos-one-23-impact-of-semaglutide-withdrawal-on-cardiometabolic-profile-and-physiology-of.md)
- [Framework for Assessing Cardiovascular Risk and Fitness for Duty in Tactical Athletes](https://medichelpline.com/clinical-feed/aha-news-0-new-guidance-introduces-framework-for-assessing-cardiovascular-risk-and-fitness.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.